Researchers designed MP0533, a multispecific CD3-engaging designed ankyrin repeat protein that could simultaneously bind to three antigens on AML cells, CD33, CD123, and CD70, aiming to enable avidity-driven T cell–mediated killing of AML cells co-expressing at least two of the antigens.
[Cancer Immunology Research]